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1. Introduction
Postherpetic  neuralgia  (PHN) is  a  form of  refractory chronic  neuralgia  that,  despite  the
importance of prevention, currently lacks any effective prophylaxis. The efficacy of live zoster
vaccine in preventing PHN was recently reported [1]. However, this vaccine appeared to be
of limited use in prophylaxis[2]. PHN has a variety of symptoms and significantly affects
patient quality of life [3-12]. Various studies have statistically analyzed predictive factors for
PHN [13-23], but neither obvious pathogenesis nor established treatment has been clarified
or established. We designed and conducted a study on the premise that statistical identifica‐
tion of significant predictors for PHN would contribute to the establishment of an evidence-
based medicine approach to the optimal treatment of PHN. As a result, we reported our
paper  “Predictive  Factors  for  Postherpetic  Neuralgia  Using Ordered Logistic  Regression
Analysis” [24].
In this review, we discuss predictors for PHN based on our results, and further review recent
pharmacotherapeutic results.
2. Predictors for PHN
Previous studies have shown that older age, female sex, presence of a prodrome, greater rash
severity, and greater acute pain severity are predictors of increased PHN [14-18, 25]. Some
other  potential  predictors  (ophthalmic  localization,  presence  of  anxiety  and  depression,
presence of allodynia, and serological/virological factors) have also been studied [14, 18]. We
conducted  a  retrospective  study  to  identify  significant  predictors  of  PHN  that  would
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contribute  to  the  establishment  of  evidence-based  medicine  approaches  to  the  optimal
treatment of PHN [24].
The participants were 73 patients with herpes zoster who had been treated at the pain clinic
of our hospital between January 2008 and June 2010. Variables present at the initial visit were
extracted from the clinical records for regression analysis of factors related to the occurrence
of PHN. The following scores for response were used: 0 = no PHN after 3 months; 1 = PHN
present after 3 months, but absent after 6 months; and 2 = PHN present after 6 months.
Multivariate ordered logistic regression analysis was performed to identify predictive factors
for PHN. Table 1 shows the clinical characteristics of patients and various factors that could
be related to the occurrence of PHN. Multivariate ordered logistic regression analysis identi‐
fied advanced age and deep pain at the initial visit to our outpatient pain clinic as factors
predicting the occurrence of PHN. diabetes mellitus (DM) and pain reduced by bathing also
showed high odds ratios, but were not significant predictive factors (Table 2). In conclusion,
advanced age and deep pain at first visit were identified as predictive factors for PHN. DM
and pain reduced by bathing should also be considered as potential predictors of PHN [24].
To improve patient safety and the likelihood of achieving satisfactory outcomes, prospective
studies are needed to establish optimal treatments including pharmacotherapy for PHN. Next
section we further review recent pharmacotherapeutic results for PHN.
(0/1) or (0/1/2), median (range)
Demographics
Significant zoster-associated pain 35/13/25
Age 8/46/19, 69 (27-90)
Sex 37/36
Complication
Hypertension 44/29
Angina 69/4
Diabetes mellitus 61/12
Malignant tumor 50/23
Autoimmune disease 68/5
Sleep disorder 36/37
Location
Trigeminal nerves 58/15
Cervical nerves 58/15
Thoracic nerves 42/31
Lumbar nerves 61/12
Sacral nerves 70/3
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(0/1) or (0/1/2), median (range)
Period of onset, type and extent of pain
Period before herpes zoster onset (days) 30 (1-3000)
Log (period before herpes zoster onset) 1.477 (0-3.477)
Prodromal rash 39/34
Prodromal pain 34/39
Allodynia 35/38
VAS (mm) 66 (0-100)
Pain reduced when bathing 41/32
Pain (superficial) 35/38
Pain (deep) 38/35
Pain (continuous) 43/30
Pain (breakthrough) 31/42
Binary scales were: female = 0, male = 1 for sex; and absent = 0, present = 1 for others.
The ordered scale was: absent after 3 months = 0, present = 1, and present after 6 months = 2 for significant zoster-
associated pain; and <50 years = 0, 51-74 years = 1, ≥75 years = 2 for age.
VAS, visual analog scale
Table 1. Clinical characteristics of 73 patients and various factors that could be related to the occurrence of PHN [24]
Variable EV SE χ2 value P OR
CI of OR
Lower 95% Upper 95%
Age 1.008 0.461 4.78 0.0288* 2.740 1.110 6.761
Prodromal pain 0.442 0.532 0.69 0.4059 1.556 0.549 4.413
DM 1.123 0.693 2.63 0.1049 3.075 0.791 11.952
Allodynia 0.201 0.630 0.10 0.7489 0.818 0.238 2.808
Pain reduced by bathing 1.221 0.745 2.68 0.1014 3.389 0.787 14.601
Deep pain 1.446 0.682 4.49 0.0341* 4.244 1.114 16.163
Breakthrough pain 0.687 0.598 1.32 0.2506 1.988 0.616 6.418
Sleep disorder 0.146 0.514 0.08 0.7757 1.158 0.423 3.169
EV, estimated value; SE, standard error; OR, odds ratio; CI, confidence interval; DM, diabetes mellitus
*P<0.05
Table 2. Results of multivariate ordered logistic regression analysis for variables extracted by forward selection with
addition of prodromal pain and allodynia [24].
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3. Recent pharmacotherapy for PHN
To date, no clear predictors of treatment response have been identified in patients with
neuropathic pain, including PHN. Various types of drugs have shown consistent efficacy in
randomized clinical trials and meta-analysis [9]. The modes of action and information on
dosing, precautions, and adverse events (AEs) for the different drug classes are summarized
in Table 3 [9]. Numbers needed to treat (NNTs), numbers needed to harm (NNH) [26, 27] and
AEs for the different drugs are shown in Table 4 [28].
Among systemic therapies, tricyclic antidepressants (TCAs), calcium channel α2-δ ligands
(gabapentin and pregabalin), and extended-release formulations of morphine and oxycodone
show good efficacy in patients with PHN. Current guidelines suggest, perhaps to maximize
the benefit-risk ratio, that TCAs should be preferred over opioids, and among TCAs, second-
generation TCAs such as nortriptyline, desipramine, and imipramine are preferred over the
first-generation agent, amitriptyline [29]. Opioids, specifically oxycodone, morphine, metha‐
done, and tramadol, are also effective against PHN. However, addiction and regulatory issues,
coupled with the benign adverse event profile of anticonvulsants, make opioids a secondary
choice in PHN [28].
The American Academy of Neurology (AAN; 2004), European Federation of Neurological
Societies (NeuPSIG; 2007), and European Federation of Neurological Societies (EFNS; 2010)
guidelines all recommend TCAs and pregabalin as first-line oral therapies for patients with
PHN [11, 30, 31]. The NeuPSIG and EFNS guidelines also recommend gabapentin as first-line
therapy for PHN. The NeuPSIG and EFNS guidelines state that secondary amine TCAs should
generally be considered instead of the tertiary amine amitriptyline, due to the superior safety
profiles [11, 29, 30].
Japan Society of Pain Clinicians (JSPC; 2011) guidelines recommend TCAs (particularly the
secondary amines), calcium channel α2-δ ligands, and extract of cutaneous tissue of rabbits
inoculated with vaccinia virus (Neurotropin®) as first-line oral therapies [32].
Mode of action Major Adverse- events
Precautions
Other benefits
Starting dose/maximum dose
Titration
Duration of adequate trial
Nortriptyline
Desipramine
Inhibition of reuptake
of
serotonin and/or
noradrenaline,
blockage of
sodium channels,
anticholinergic
Sedation, ant-cholinergic
effects (e.g., dry
mouth or urinary
retention, weight gain)
Cardiac disease ,
glaucoma, seizure
disorder, use of
tramadol
Improvement of
depression and
25 mg at bedtime/150 mg daily
Increase by 25 mg every 3-7 day as
tolerated
6-8 weeks (at least 2 weeks
Maximum tolerated dose)
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Mode of action Major Adverse- events
Precautions
Other benefits
Starting dose/maximum dose
Titration
Duration of adequate trial
sleep disturbance
Gabapentin Decreases release of
glutamate,
noradrenaline,
and substance P, with
ligands
on α2-δ subunit of
voltage-gated calcium
channel
Sedation, dizziness, peripheral
edema
Renal Insufficiency
No clinically significant drug
interactions
100-300 mg once to
three times
daily/1200 mg three
times daily; reduce if
renal function impaired
Increase by
100-300 mg three
times daily every
1-7 days as
Tolerated
4 weeks
Pregabalin Decreases release of
glutamate,
noradrenaline,
and substance P, with
ligands on α2-δ
subunit of voltage-
gated calcium
channel
Sedation, dizziness,
Peripheral edema
Renal Insufficiency
No clinically significant drug
interactions,
improvement of sleep
disturbance and anxiety
50 mg three times daily
or 75 mg twice
daily/200 mg three
times or 300 mg twice
daily, reduce if
renal function impaired
Increase to 300 mg
daily after
3-7 days, then by
150 mg daily every
3-7 days, as
Tolerated
4 weeks
5% lidocaine
patch
Blockage of sodium
channels
Local erythema,
Rash
None
No systemic adverse events
1-3 patches/3 patches
None
2 weeks
Morphine,
oxycodone,
methadone,
levorphanol
µ-receptor agonism
(oxycodone also
causes
к-receptor
antagonism)
Nausea/
vomiting,
constipation,
dizziness
History of substance
abuse, suicide risk,
driving impairment
Rapid onset of
analgesic effect
10-15 mg morphine
every 4 h or as needed
(equianalgesic doses
should be used for other opioids)/no
maximum doses
After 1-2 weeks
convert to long-acting
opioids/
transdermal
application, use
short-acting drug
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Mode of action Major Adverse- events
Precautions
Other benefits
Starting dose/maximum dose
Titration
Duration of adequate trial
as needed and as
tolerated
4-6 weeks
Recommendations are all grading level A = good scientific evidence suggesting that the benefits of the treatment
substantially outweigh the potential risks.
Table 3. Recommended first-line treatments for patients with PHN [9]
Drug NNT (95%CI) NNH (95%CI) Specific/Common Adverse Effects
Amitriptyline 1.6 (1.2-2.4)
4.2 (2.13-81.6)
Minor harm:
8 (2.5-22)
Major harm:
24 (8-36)
Sedation, dry mouth, tachycardia,
constipation, urinary retention, weight gain,
prolonged QT interval
Desipramine 1.9 (1.3-3.7) Minor harm: 4.8 (2.5-36.7)
Major harm: 13*
Nortriptyline 3.7 (2.4-8) ND
Gabapentin 4.4 (3.3-6.1) Minor harm: 4.1 (3.2-5.7)
Major harm: 12.3 (7.7-30.2)
Somnolence, dry mouth, weight gain,
peripheral edema, ataxia
Pregabalin 4.9 (3.7-7.6) Minor harm: 4.3 (2.8-9.2)
Major harm: ND
Dizziness, somnolence, peripheral edema
Oxycodone 2.5 (1.7-4.4) Minor harm: 3.6 (2.2-10.2)
Major harm: 6.3 (4.2-12.8)
Immune suppression, loss of libido,
endocrine dysfunction
Morphine-
controlled
release or
methadone
2.8 (2-4.6) ND
Tramadol 4.8 (3.5-6.0) Minor harm: 7.2*
Major harm: 10.8*
Somnolence, constipation, nausea and
vomiting,
seizures, serotonin syndrome when
combined
with SSRIs and MAO inhibitors
Values for NNTs and NNHs were adapted from Hempenstall et al. [27] and Wu and Raja [26]. NNTs for amitriptyline were
based on studies by Watson et al. [49] and Max et al. [50].
*The 95% confidence interval (CI) could not be determined by Hempenstall et al. [27] or by Wu and Raja [26].
ND, could not be determined by Hempenstall et al [27]; SSRIs, selective serotonin reuptake inhibitors; MAO, monoamine
oxidase
Table 4. NNT, NNH, and adverse effects of selected drugs for PHN [28]
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3.1. Calcium hannel α2-δ Ligands
Gabapentin and pregabalin suppress the release of excitatory neurotransmitters on binding to
the α2-δ subunit of potential-dependent calcium channels in the central nervous system (CNS).
Both drugs are structurally similar and share similar mechanisms of action, but pregabalin
shows a linear pharmacokinetic profile and strong affinity for the α2-δ subunit. Both drugs
have been widely studied in peripheral pain syndromes, although pregabalin has been the
focus of most studies in central neuropathic pain syndromes. Only a few drug interactions
have been reported for both drugs and the agents are well tolerated, but must be used at lower
doses in patients with decreased renal function [9, 32]. The EFNS, AAN, and NeuPSIG
guidelines recommend the calcium channel α2-δ ligands gabapentin and/or pregabalin for the
treatment of PHN [11, 29-31]. In a meta-analysis, NNTs before 1 patient achieves 50% pain
reduction for gabapentin (3 trials, 559 patient episodes) and pregabalin (3 trials, 411 patient
episodes) for a 50% reduction in pain were 4.4 and 4.9, respectively [27, 29] (Table 4). Subse‐
quent Cochrane reviews for both drugs calculated NNTs of 7.5 for gabapentin [29, 33] and 3.9
for pregabalin 600 mg [29, 34]. Gabapentin and pregabalin are effective and are the most
commonly prescribed drugs in PHN because of their efficacy and benign AEs profile.
3.1.1. Pregabalin
Pregabalin is a 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convul‐
sant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanisms of
action are unclear, pregabalin selectively binds to α2-δ subunits of presynaptic voltage-
dependent calcium channels located in the CNS. Binding of pregabalin to α2-δ subunits of
presynaptic voltage-dependent calcium channels prevents calcium influx and the subsequent
calcium-dependent release of various neurotransmitters, including glutamate, noradrenaline,
serotonin (5-Hydroxytryptamine: 5-HT), dopamine, and substance P, from the presynaptic
nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal
excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors
and does not alter GABA uptake or degradation [35].
Pregabalin has also been associated with dose-related risks of somnolence (5-14%), dizziness
(7-28%), and peripheral edema (6-16%) [29, 32, 34]. At a higher dose (600 mg/day), pregabalin
has been associated with weight gain (9%), asthenia (9%), dry mouth (6%), and vertigo (5%)
[28, 29, 36]. Discontinuations due to these AEs were ≤1% in patients treated with pregabalin
at 150 mg/day and 4-15% in patients receiving a 600-mg/day dose. Serious AEs were reported
in 2-5% of patients treated with pregabalin at 150, 300, and 600 mg/day, compared with 3% in
those assigned to receive a placebo [29, 36]. Symptoms including insomnia, nausea, headache,
and diarrhea were reported by some patients following abrupt withdrawal of pregabalin.
Pregabalin should therefore be tapered gradually over a minimum of 1 week rather than
discontinued abruptly. Weight gain noted in clinical trials of pregabalin was not limited to
patients with peripheral edema. Weight gain was related to dose and duration of exposure to
pregabalin, but did not appear to be associated with sex, age, or baseline body-mass index. A
higher incidence of weight gain and peripheral edema were noted in patients taking both
Predictive Factors for Postherpetic Neuralgia and Recent Pharmacotherapies
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pregabalin and a thiazolidinedione, compared with patients taking either agent alone. As a
result, care should be taken when co-administering pregabalin and one of these agents [37].
JSPC guidelines recommend beginning pregabalin treatment at 75 mg/day once before bed,
150 mg/day as two doses after breakfast and supper, or 150 mg/day as three doses after each
meal. Even when renal function is normal, consider a very low dose only just before bed, such
as 25 mg/day once before bed, for elderly patients, patients of low body weight, and others
prone to AEs [32].
3.1.2. Gabapentin
Gabapentin is a synthetic analogue of the neurotransmitter GABA with anticonvulsant
activity. Although the exact mechanisms of action are unknown, gabapentin appears to inhibit
excitatory neuron activity. This agent also exhibits analgesic properties [35].
In clinical trials, the most frequent AEs observed with gabapentin were somnolence (16%),
dizziness (21%), and peripheral edema (8%) [33]. Twelve percent of patients discontinued
gabapentin owing to AEs, compared with 8% who discontinued placebo. Serious AEs with
gabapentin and placebo occurred in 4% and 3% of patients, respectively [29].
3.2. Opioids
Opioid analgesics are agonists at presynaptic and postsynaptic opioid receptors. Opioids offer
comparable analgesic efficacy to TCAs. Concerns about long-term AEs, such as immunological
changes, physical dependency, and misuse or abuse, can limit the use of strong opioids in
patients with neuropathic non-cancer-related pain [9].
The place of opioids and tramadol in guidelines for the management of PHN has evolved over
time. In the 2004 AAN guidelines, extended-release formulations of oxycodone and morphine
were recommended as first-line agents. Guidelines issued by the NeuPSIG (2007) and EFNS
(2010) recommend strong opioids and tramadol as second-line therapy, not because of new
data on efficacy, but perhaps reflecting concerns about the risks of AEs and abuse [29].
Extended-release formulations of oxycodone [38] and morphine, as well as methadone [39],
have shown efficacy in patients with PHN. The NNT for a 50% reduction in pain were 2.5 for
oxycodone and 2.8 for morphine or methadone, compared with an NNT of 3.7 for the TCA
nortriptyline (Table 4). In a placebo-controlled, active comparator-controlled crossover trial,
the majority of patients (53%) preferred the opioids morphine or methadone over TCAs.
Opioids tended to provide greater pain relief, although the difference was not significant [40].
A meta-analysis of the 2 trials evaluating oxycodone, morphine and methadone calculated an
NNT for opioids of 2.7 [27]. Tramadol has proven less effective than strong opioids. In a
randomized controlled trial, tramadol was not significantly better than placebo on a 5-point
verbal scale or on measures of quality of life [40]. An analysis of this trial calculated an NNT
of 4.8 [27]. Oxycodone, morphine, and methadone were associated with typical opioid-related
AEs, including nausea, diarrhea, and constipation [38, 39]. Tramadol was better tolerated, but
less effective [40].
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In the JSPC guideline, although multiple clinical studies have demonstrated the analgesic
effects of opioid analgesics (narcotics for medical use) in patients with neuropathic pain,
opioids are generally recommended as second- or third-line treatment for several reasons.
First, opioid analgesics have a high incidence of associated AEs that may persist over the entire
course of treatment. Second, the lack of any systematic investigation into the long-term safety
of opioid analgesics means that the opioid analgesics may not be fundamentally safer than
other drug options. Third, opioid analgesics may cause hyperalgesia. This effect, if present,
would adversely modify the risk/benefit profile of long-term treatment in neuropathic pain
patients. Finally, opioid abuse and addiction are substantial problems [32].
3.2.1. Morphine
The sulfate salt of morphine is an opiate alkaloid isolated from the plant Papaver somniferum
and produced synthetically. Morphine binds to and activates specific opiate receptors (δ, μ and
κ), each of which are involved in controlling different brain functions. In the CNS and gastroin‐
testinal system, this agent exerts widespread effects including analgesia, anxiolysis, euphoria,
sedation, respiratory depression, and smooth muscle contraction in the gastrointestinal system.
A sustained-release tablet formulation contains the sulfate salt of the opiate alkaloid morphine
to provide analgesic activity. Morphine binds to and activates μ-opioid receptors in the CNS,
thereby mimicking the effects of endogenous opioids. Binding of morphine to opioid receptors
stimulates exchange of guanosine 5'-triphosphate for guanosine 5'-diphosphate, inhibits
adenylate cyclase, and decreases intracellular cyclic adenosine monophosphate. This inhibits
the release of various nociceptive neurotransmitters, such as substance P, GABA, dopamine,
acetylcholine, noradrenaline, vasopressin, and somatostatin. In addition, morphine closes N-
type voltage-gated calcium channels and opens calcium-dependent inwardly rectifying
potassium channels, causing hyperpolarization of neuronal membranes and reductions in
neuronal excitability, with subsequent analgesia and sedation [35].
3.2.2. Oxycodone hydrochloride
The hydrochloride salt of oxycodone is a methylether of oxymorphone and a semisynthetic
opioid agonist with analgesic and antitussive properties. Oxycodone binds to μ-receptors in
the CNS, thereby mimicking the effects of endogenous opiates as well as morphine. In addition
to analgesia and a depressive effect on the cough center in the medulla, this agent may cause
euphoria, anxiolysis, miosis, sedation, physical dependence, constipation, and respiratory
depression, depending on dosage and variations in individual metabolism [35].
3.2.3. Tramadol
A synthetic codeine analogue, tramadol has central analgesic properties with effects similar to
opioids, such as morphine and codeine, acting on specific opioid receptors. Used as a narcotic
analgesic for severe pain, this agent can be addictive. Tramadol is used to treat moderate-to-
severe pain in adults, and binds to opioid receptors in the CNS[41]. Tramadol also weakly inhibits
noradrenaline and 5-HT reuptake and can therefore interact with serotonergic drugs (selec‐
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tive noradrenaline reuptake inhibitors [SNRIs] and selective serotonin reuptake inhibitors
[SSRIs]), causing serotonin syndrome, although this risk seems to be low in clinical practice [9].
3.3. TCAs
Clinical data support the efficacy of TCAs for PHN. In a 2005 meta-analysis of 4 clinical trials
(248 patient episodes), the NNT for 1 patient to achieve a 50% reduction in pain with the TCAs
amitriptyline, nortriptyline, and desipramine was 2.6 [27]. A 2007 Cochrane review of 4 clinical
trials (244 patients) calculated an NNT of 2.7 [41]. Although effective, TCAs have been
associated with significant systemic AEs, most notably anticholinergic AEs [43, 44], and have
been associated with cardiotoxicity [45-47]. Electrocardiography (ECG) before the start of
treatment is mandatory and careful dose titration is needed [9]. Individual trials of amitripty‐
line and desipramine in patients with PHN suggest that the second-generation TCA desipra‐
mine produces fewer anticholinergic side effects than amitriptyline [48, 49].
3.3.1. Amitriptyline hydrochloride
The hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepres‐
sant and antinociceptive activities. Amitriptyline hydrochloride is the hydrochloride salt of
the tricyclic dibenzocycloheptadiene amitriptyline, and shows antidepressant and antinoci‐
ceptive activities. Amitriptyline inhibits the re-uptake of noradrenaline and serotonin by the
presynaptic neuronal membrane in the CNS, thereby increasing synaptic concentrations of
noradrenaline and serotonin. Due to constant stimulation of these receptors, amitriptyline may
produce a downregulation of adrenergic and serotonin receptors, which may contribute to the
antidepressant activity. In the CNS, the antinociceptive activity of this agent may involve high-
affinity binding to and inhibition of N-methyl-D-aspartate (NMDA) receptors and/or en‐
hancement of the action of serotonin at the spinal terminals of an opioid-mediated intrinsic
analgesia system [35].
Amitriptyline has an NNT of 2.2 for PHN, but the AEs, lack of recommendations for use in the
elderly, and small sample sizes of studies have relegated this agent behind antiepileptics for
certain PHN cases [30, 42, 50, 51]. Nortriptyline, maprotiline, and desipramine have also
proven effective, but less so than amitriptyline.
3.3.2. Nortriptyline
A TCA used for short-term treatment of various forms of depression, nortriptyline blocks the
noradrenaline presynaptic receptors, thereby blocking reuptake of this neurotransmitter and
raising concentrations in the synaptic cleft in the CNS. Nortriptyline also binds to α-adrenergic,
histaminergic and cholinergic receptors. Long-term treatment with nortriptyline produces
downregulation of adrenergic receptors due to increased stimulation of these receptors [41].
3.4. Selective serotonin and noradrenaline reuptake inhibitors
Patients who are unable to tolerate TCAs may do better with selective serotonin and noradre‐
naline reuptake inhibitors, such as duloxetine or venlafaxine. Although less effective than
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TCAs, the selective 5-HT and noradrenaline reuptake inhibitors (SSNRIs) offer efficacy for
both pain and depression with fewer AEs. SSRIs effectively relieve depression symptoms but
they do not specifically relieve neuropathic pain. Nevertheless, some patients with chronic
pain due to PHN will experience clinical depression, and the use of SSRIs can be useful for the
management of depressive symptoms [5].
SNRIs are safer and easier to use than TCAs and represent a better option for patients with
heart disease. The mechanism of SNRI analgesia is likely associated with activation of the
descending inhibitory system of pain.
3.4.1. Paroxetine hydrochloride
The hydrochloride salt form of paroxetine is a phenylpiperidine derivative and a SSRI with
antidepressant and anxiolytic properties. Paroxetine binds to the pre-synaptic serotonin
transporter complex, resulting in negative allosteric modulation of the complex and thereby
blocking reuptake of serotonin by the pre-synaptic transporter. Inhibition of serotonin
recycling enhances serotonergic function through serotonin accumulation in the synaptic cleft,
resulting in long-term desensitization and downregulation of 5-HT receptors and leading to
symptomatic relief of depressive illness [35].
3.4.2. Duloxetine hydrochloride
The hydrochloride salt of duloxetine is a fluoxetine derivative belonging to the class of SSNRIs
and exhibiting antidepressant activity. Duloxetine selectively prevents reuptake of 5-HT and
noradrenaline via transporter complexes on the pre-synaptic membrane, thereby increasing
the levels of these neurotransmitters within the synaptic cleft. As a result, this agent potentiates
serotonergic and noradrenergic activities in the CNS, alleviating depression and neuropathic
sensations such as pain and tingling. Furthermore, duloxetine does not show significant
affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamatergic, or
GABAergic receptors [35].
Duloxetine is recommended for painful diabetic neuropathies [11, 29, 30], but not for PHN;
little clinical trial data has been accumulated supporting use in PHN. SNRIs are also associated
with a number of systemic AEs, including nausea, vomiting, somnolence, anorexia, constipa‐
tion, dizziness, fatigue, insomnia, increased sweating, and dry mouth [52-54].
3.5. Other oral therapies
Several other oral agents have been investigated in the treatment of PHN. Specifically, the
NMDA antagonists dextromethorphan and memantine [55, 56] and the benzodiazepine
lorazepam [56] have not shown good efficacy in clinical trials.
In treatment guidelines, therapies described as lacking sufficient evidence of efficacy include
anticonvulsants that target sodium channels (carbamazepine and oxcarbazepine), other
anticonvulsants (lamotrigine, topiramate, and valproic acid), other antidepressants (bupro‐
pion, citalopram, paroxetine), and the oral lidocaine analog, mexiletine [11, 30, 31]. For other
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neuropathic pain syndromes, mexiletine has only shown efficacy at doses that produce
systemic AEs, including proarrhythmic effects [43]. This suggests that the benefits of sodium
channel antagonism for PHN may be better achieved via local lidocaine administration.
JSPC guidelines also recommend extract of cutaneous tissue from rabbits inoculated with
vaccinia virus (Neurotropin®) as a first-line oral therapy[32].
3.5.1. Carbamazepine
Carbamazepine is a tricyclic compound chemically related to TCAs with anticonvulsant and
analgesic properties. This agent exerts anticonvulsant activity by reducing polysynaptic
responses and blocking post-tetanic potentiation. The analgesic activity is not understood, but
carbamazepine is commonly used to treat pain associated with trigeminal neuralgia [35].
3.5.2. Valproic acid
Valproic acid is a synthetic derivative of propylpentanoic acid with antiepileptic properties
and potential antineoplastic and antiangiogenesis activities. In epilepsy, valproic acid appears
to act by increasing concentrations of GABA in the brain. The antitumor and antiangiogenesis
activities of this agent may be related to the inhibition of histone deacetylases and nitric oxide
synthase, resulting in the inhibition of nitric oxide synthesis [35].
3.5.3. Extract of cutaneous tissue from rabbits inoculated with vaccinia virus
Extract of cutaneous tissue from rabbits inoculated with vaccinia virus (Neurotropin®) has
been shown to exert analgesic effects in a Japanese clinical study in PHN as one type of
neuropathic pain. Producing no serious AEs, the drug product was very well tolerated, in
addition to conferring analgesic effects. The drug product has been clinically used in patients
20 years old and older and is very safe [32, 57, 58].
3.5.4. Antiarrhythmics (mexiletine)
Mexiletine hydrochloride is a class 1B antiarrhythmic, and works by blocking sodium
channels. A local anesthetic and antiarrhythmic (Class IB) agent structurally related to
lidocaine, mexiletine exerts antiarrhythmic effects by inhibiting the inward sodium current in
cardiac cells, thus reducing the rate of increase in the cardiac action potential (phase 0) and
decreasing automaticity in Purkinje fibers. This slows nerve impulses in the heart and stabilizes
the heartbeat. The anesthetic activity is due to the ability of mexiletine to block sodium influx
in peripheral nerves, thereby reducing the rate and intensity of pain impulses reaching the
CNS [41].
3.5.5. Lidocaine patch 5%
Lidocaine relieves pain through non-specific blockage of sodium channels on ectopic periph‐
eral afferent fibers without causing numbness of the treated skin. Topical application without
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a relevant systemic absorption offers a good benefit-to-risk ratio only with local AEs, such as
erythema or rash [9].
The transdermal patch contains a 5% aqueous base solution of the synthetic amide-type
anesthetic lidocaine with analgesic activity. Upon topical application and transdermal
delivery, the active ingredient lidocaine binds to and blocks voltage-gated sodium channels
in the neuronal cell membrane; lidocaine-mediated stabilization of neuronal membranes
inhibits the initiation and conduction of nerve impulses and produces reversible local anes‐
thesia [34]. The lidocaine 5% patch is recommended as first-line therapy in the AAN [31],
NeuPSIG [30], and EFNS [11] guidelines [29].
3.6. Combination therapy
In clinical practice, a combination of two or more drugs is often needed to achieve satisfactory
pain relief, although few trials have been conducted to support this clinical observation.
However, combination therapy with gabapentin or pregabalin and extended-release morphine
in patients with PHN achieved higher pain relief with lower doses compared to administration
of one drug alone. These results have also been confirmed for the combination of nortriptyline
and gabapentin as well as for pregabalin and topical lidocaine in patients with PHN. Taken
together, these results substantiate the usefulness of combination therapies in patients with
PHN [9].
4. Conclusion
Neither obvious pathogenesis nor an established treatment have been clarified or established
for PHN. Our study indicated that advanced age and deep pain at the first visit were shown
to be predictive factors for PHN. DM and pain reduced by bathing should also be considered
as potential predictors of PHN. We further reviewed recent pharmacotherapeutic results for
PHN. To improve patient safety and the likelihood of achieving satisfactory outcomes,
prospective studies are needed to establish optimal treatments including pharmacotherapy
for PHN.
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